Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Download Data

Relmada Therapeutics Inc Gross Profit Margin for the year ending December 31, 2023

Relmada Therapeutics Inc Gross Profit Margin is NA for the year ending December 31, 2023. Gross Profit Margin represents the percentage of revenue that represents gross profit, indicating the efficiency of a company's production and pricing.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends